Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Revolution Medicines Inc RVMD

Alternate Symbol(s):  RVMDW

Healthcare Biotechnology
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RVMD)

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

GlobeNewswire 3 days ago

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

GlobeNewswire April 9, 2024

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

GlobeNewswire April 8, 2024

Revolution Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire April 4, 2024

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

GlobeNewswire March 28, 2024

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

GlobeNewswire February 26, 2024

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

GlobeNewswire February 20, 2024

Revolution Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire February 1, 2024

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2024
View More News ››

Opinion & Analysis (NDAQ:RVMD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RVMD)

Be the first to post on this bullboard.

Heritage Mining Ltd.

Heritage Mining Ltd.

Heritage Mining Ltd. is focused on acquiring and developing Tier-1 advanced stage precious and base metal exploration ...
View More »